ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) is Buildings and Property in Germany that focus on cancer drug development license business. They cover business area such as Germany, patient, metastatic castration-resistant prostate cancer.
-
Cancer Drug Development License
-
Heinrich - Glaeser - Strasse 10 - 14
01454 Radeberg
Germany
Private
Germanypatientmetastatic castration-resistant prostate cancer
* We use standard office opening hours in near ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate )'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) is Buildings and Property business from Germany that founded in - ( years old in ), ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) business is focusing on Cancer Drug Development License.
ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) headquarter office and corporate office address is located in Heinrich - Glaeser - Strasse 10 - 14 01454 Radeberg Germany.
ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) was founded in Germany.
In , ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ) is currently focus on cancer drug development license sector.
Above is snippet of Google Trends for "cancer drug development license" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with ABX Advanced Biochemical Compounds (177Lu-PSMA-617 Prostate Cancer Candidate ), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
